Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015–2022
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciad699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Kavita Misra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bureau of Hepatitis, HIV and STIs, New York City Department of Health and Mental Hygiene, Queens, New York, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Drug resistance may be acquired in people starting human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) during undiagnosed infection. Population-based estimates of PrEP-related resistance are lacking.
Methods
We used New York City surveillance and partner services data to measure the effect of PrEP use (tenofovir disoproxil fumarate/tenofivir alafenamide fumarate with emtricitabine) history on the baseline prevalence of M184I/V mutations in people with HIV diagnosed in 2015–2022. PrEP use was categorized as “recent” (defined as PrEP stopped ≤90 days before diagnosis), “past” (PrEP stopped >90 days before diagnosis), or “no known use.” Resistance-associated mutations were determined using the Stanford algorithm. We used log binomial regression to generate the adjusted relative risk (aRR) of M184I/V by PrEP use history in people with or without acute HIV infection (AHI).
Results
Of 4246 people with newly diagnosed HIV and a genotype obtained within ≤30 days of diagnosis, 560 (13%) had AHI; 136 (3%) reported recent and 124 (35%) past PrEP use; and 98 (2%) harbored M184I/V. In people with AHI, recent PrEP use was associated with a 6 times greater risk of M184I/V than no known use (aRR, 5.86 [95% confidence interval, 2.49–13.77]). Among people without AHI, the risk of M184I/V in recent users was 7 times that in people with no known use (aRR, 7.26 [95% confidence interval, 3.98–13.24]), and in past users, it was 4 times that in those with no known use (4.46 [2.15–9.24]).
Conclusions
PrEP use was strongly associated with baseline M184I/V in New York City, regardless of AHI status. Ordering a nucleic acid test when indicated after assessment of exposure, antiretroviral history, and AHI symptoms can decrease PrEP initiation in people with undetected infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bureau of Hepatitis, HIV and STIs, New York City Department of Health and Mental Hygiene, Queens, New York, USA.
ORCID-Profile: Kavita Misra, Qiang Xia
Zitieren
APA
Misra, K., Huang, J. S., Udeagu, C. N., Forgione, L., Xia, Q., & Torian, L. V. (2024). Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015–2022. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad699
Vancouver
Misra K, Huang JS, Udeagu CN, Forgione L, Xia Q, Torian LV. Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015–2022. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad699
BibTeX
@article{Misra2024,
author = {Misra, Kavita and Huang, Jamie S and Udeagu, Chi-Chi N and Forgione, Lisa and Xia, Qiang and Torian, Lucia V},
title = {Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015–2022},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciad699}
}
EUVIMED